OCU410 has a very favorable safety and tolerability profile No serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular ...
TORONTO, May 02, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ...
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
Please provide your email address to receive an email when new articles are posted on . The ArMaDa trial is investigating unilateral subretinal administration of OCU410, a gene therapy for geographic ...
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of ...
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema Provided by GlobeNewswire ...
Data Monitoring Committees (DMCs) play a pivotal role in safeguarding participant safety and ensuring the integrity of clinical trials. Operating independently from trial sponsors and investigators, ...
The Africa Centres for Disease Control and Prevention (Africa CDC) is an autonomous institution of the African Union that supports the Member States (MS) in planning, preparing and responding to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results